High-density lipoproteins anti-atherogenicity

Ciprofibrate 131 is a potent, long-acting hypolipidemic agent. It is effective in type Ila, Ilb, III and IV hyperlipoproteinemias and produces a beneficial elevation of the anti-atherogenic high density lipoprotein, Eq. (52) [182]. 

Low-fat, high-carbohydrate diets have been shown to lower plasma low-density lipoprotein (LDL) cholesterol levels. At the same time, these diets decrease anti-atherogenic high-density lipoprotein (HDL)-cholesterol, and increase concentrations of plasma triglycerides, lipoprotein[a] (Lp[a]), and small dense LDL, plus increasing insulin resistance. Overall, these changes are likely to increase the risk of coronary heart disease (Willett, 2002 Kris-Etherton et al., 2002 Sanders, 2003). 

Fatty acids play an important role as a risk factor for cardiovascular diseases, that is by forming plaques within the arteria. Low density lipoproteins (LDL) are seen as the most important risk factor. In the clinical chemistry laboratory, both LDLs and HDLs (high density lipids, considered as an anti-atherogenic factor) are determined. 

---